| abstract |
IT REFERS TO METASTINE DERIVATIVES WHERE CERTAIN AMINO ACIDS HAVE BEEN SUBSTITUTED, FROM FORMULA (I), WHERE V 'IS A GROUP a), AMONG OTHERS; EACH Z1, Z5 AND Z7 REPRESENTS A H O ALKYL (C1-C3); EACH OF Z2, Z4, Z6 AND Z8 IS H, O, or S; R1 IS H, ALKYL (C1-C8) OPTIONALLY SUBSTITUTED WITH HYDROXYL, CARBAMOYL, AMONG OTHERS; R2 IS H, ALKYL (C1-C10) CYCLICAL OR LINEAR, ALKYL (C1-C8), OPTIONALLY SUBSTITUTED, AMONG OTHERS; R3 IS RENTAL (C1-C8) THAT HAS AN OPTIONALLY SUBSTITUTE BASIC GROUP AND AN ADDITIONAL SUBSTITUTE, AMONG OTHERS; R4 IS ALKYL (C1-C4) OPTIONALLY SUBSTITUTED WITH AROMATIC FUSED HETEROCYCLIC AMONG OTHERS; Q1 IS RENTAL (C1-C4) OPTIONALLY SUBSTITUTED, AMONG OTHERS; A IS N O C SUBSTITUTED WITH H, O IS S; Q2 IS CH2, CO, CS, CH2 = CH2, OPTIONALLY SUBSTITUTED, AMONG OTHERS. ARE SELECTED: Ac-D-Tyr-Hyp-Asn-Thr-Cha-Gly-Ala (cPr) -Arg (Me) -Trp-NH2, Ac-D-Tyr-Hyp-Asn-Thr-Cha-Gly-? (euroCH = CH) Leu-Arg-Trp-NH2, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS HAVE A CANCER METASTASIS SUPPRESSIVE ACTIVITY OR A CANCER GROWTH SUPPRESSIVE ACTIVITY IN ADDITION TO ACHIEVING GREATER STABILITY, SOLUBILITY IN COMPARISON WITH NATIVE METASTIN |